Toronto Innovation Acceleration Partners
VC Fund
Toronto, Canada
Toronto Innovation Acceleration Partners is a VC fund in Toronto focused on Health Care and Biotechnology. MaRS Innovation (MI) is a commercialization engine that integrates, centralizes and accelerates time to market of the discovery and intellectual property assets from its 15 world-class research institutions. MI’s discovery and innovation pipeline is derived from $1 billion in annual R&D funding. Created as a not-for-profit organization through the Government of Canada’s Center of Excellence for Commercialization and Research program (CECR), MI has raised $50 million from federal and provincial governments, member institutions and industry partners. MI’s vision is to transform the Toronto-based research enterprise into one of world’s most successful commercialization clusters. Through detailed, market facing due diligence, MI identifies opportunities from Canada’s largest academic cluster for further development and commercialization through project management, intellectual property management, investment and technology development. By crossing the innovation gap, MI transforms these opportunities into successful high-value licensing transactions and financeable start-up companies.
- Total investments:
- 87
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Toronto Innovation Acceleration Partners invests in
Stages Toronto Innovation Acceleration Partners invests in
Countries Toronto Innovation Acceleration Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Seed
- $73k–$8M
- Grant
- $13k–$100k
- Pre-Seed
- $22k–$525k
Investment Focus
Industry
- Health Care 26 (30%)
- Biotechnology 20 (23%)
- Software 14 (16%)
- Artificial Intelligence 10 (11%)
- Medical 9 (10%)
Stage
- Seed 27 (31%)
- Pre-Seed 26 (30%)
- Grant 16 (18%)
- Series A 5 (6%)
- Venture - Series Unknown 4 (5%)
Country
- Canada 67 (77%)
- United States 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ben Rogers
Director
|
Director | Total investments: 0 | Find email | |
Dominic Jaikaran
Director
|
Director | Total investments: 0 | Find email | |
Mark Zdziebko
Manager
|
Manager | Total investments: 0 | Find email | |
Prakash Gowd
Vice President
|
Vice President | Total investments: 1 | Find email | |
Susanne Staer
Manager
|
Manager | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Grey Matter Neurosciences is a neurotechnology firm developing new medical devices and drug-device combinations to treat age-related brain illnesses like dementia. | $14M / Seed / Jan 23, 2025 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $35M / Series A / Sep 11, 2024 | ||
| HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | $3.2M / Seed / Sep 05, 2024 | ||
| AmacaThera is a clinical-stage company based in Toronto. AmacaThera is redefining how therapeutics are delivered. AmacaThera has developed a platform hydrogel technology that addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. AmacaThera’s lead product addresses post-operative painand consequently may have an impact on the opioid crisis. | $50K / Grant / Dec 01, 2023 | ||
| Spero Analytics is an environmental technology startup which designs and deploys environmental monitoring IoT networks for methane surveillance in landfills. | $165.6K / Pre-Seed / Sep 01, 2023 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $8M / Seed / Apr 25, 2023 | ||
| NerveX has developed ANIMO, the adaptive neural implant for modulation and observation. ANIMO is a vessel to implant our proprietary machine learning and responsive electrical neuromodulation technology to repair and augment the nervous system. | $75K / Grant / Mar 01, 2023 | ||
| Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension. | $12.5K / Grant / Mar 01, 2023 | ||
| Genetics Adviser is a web application that helps the patients to access counseling content and provides genetics health services. | Seed / Jan 01, 2023 | ||
| Damona Pharmaceuticals is a pre-clinical pharmaceutical company treats and prevents cognitive deficits in a variety of brain disorders and during aging. | $5.5M / Seed / Sep 26, 2022 | ||
| See all 87 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Toronto Innovation Acceleration Partners invest in?
Toronto Innovation Acceleration Partners invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Pre-Seed stage. Most of the 87 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Toronto Innovation Acceleration Partners invest in?
Toronto Innovation Acceleration Partners typically joins rounds of $73k–$8M at Seed, $13k–$100k at Grant and $22k–$525k at Pre-Seed. These are whole funding-round sizes, not Toronto Innovation Acceleration Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Toronto Innovation Acceleration Partners took part in.
How do I contact Toronto Innovation Acceleration Partners?
Public channels for Toronto Innovation Acceleration Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Toronto Innovation Acceleration Partners?
The team at Toronto Innovation Acceleration Partners includes Ben Rogers (Director), Dominic Jaikaran (Director) and Mark Zdziebko (Manager), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
